Kairos Pharma, Ltd. (KAPA) Income Statement Analysis

See more : Quest Patent Research Corporation (QPRC) Income Statement Analysis – Financial Results

Complete financial analysis of Kairos Pharma, Ltd. (KAPA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kairos Pharma, Ltd., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Taiwan Environment Scientific Co., Ltd. (8476.TW) Income Statement Analysis – Financial Results
AUO Corporation (2409.TW) Income Statement Analysis – Financial Results
Public Joint Stock Company Aeroflot – Russian Airlines (AFLT.ME) Income Statement Analysis – Financial Results
Meredith Corporation (0K0J.L) Income Statement Analysis – Financial Results
SVP Global Textiles Limited (SVPGLOB.BO) Income Statement Analysis – Financial Results

Kairos Pharma, Ltd. (KAPA)

Industry: Biotechnology

Sector: Healthcare

Website: https://kairospharma.com

About Kairos Pharma, Ltd.

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.

Unable to fetch income statement for: KAPA

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

December 3, 2024businesswire.com

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the addition of City of Hope Cancer Center in Duarte, California to the Phase 2...

IBN Initiates Coverage of Kairos Pharma Ltd.

November 26, 2024globenewswire.com

LOS ANGELES, Nov. 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics, has selected IBN, a multifaceted financial news and publishing company for private and...

Kairos Pharma to Present at the LD Micro Main Event XVII

October 22, 2024globenewswire.com

LOS ANGELES, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, will present a corporate overview at the LD Micro Main Event XVII....

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

October 9, 2024globenewswire.com

LOS ANGELES, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual...

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

September 24, 2024globenewswire.com

LOS ANGELES, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a groundbreaking collaboration with PreCheck Health Services Inc., a CLIA-certified and CAP-accredited clinical laboratory specializing in genetic sequencing. The partnership focuses...

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

September 21, 2024seekingalpha.com

Two small IPOs and two SPACs debuted this past week - Global Engine, Kairos Pharma, YHN Acquisition I, and Cayson Acquisition, respectively. Seven IPOs and three SPACs submitted initial filings. Eight companies are expected to price their IPOs in the...

Kairos Pharma Closing of $6.2 Million Initial Public Offering

September 17, 2024globenewswire.com

LOS ANGELES, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (“Kairos Pharma” or the “Company”) (NYSE American: KAPA), a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune suppression, announces that it has...

Kairos Pharma Prices $6.2 Million Initial Public Offering

September 16, 2024globenewswire.com

Company anticipates commencement of trading on the NYSE American effective September 16, 2024 under the symbol “KAPA” Company anticipates commencement of trading on the NYSE American effective September 16, 2024 under the symbol “KAPA”